A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 microg plus formoterol 6 microg/actuation), 2 puffs b.i.d., versus beclomethasone diproprionate HFA (250 microg/actuation), 4 puffs b.i.d., versus Seretide 500/50 (fluticasone 500 microg plus salmeterol 50 microg/actuation), 1 inhalation b.i.d., in patients with severe asthma

Trial Profile

A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 microg plus formoterol 6 microg/actuation), 2 puffs b.i.d., versus beclomethasone diproprionate HFA (250 microg/actuation), 4 puffs b.i.d., versus Seretide 500/50 (fluticasone 500 microg plus salmeterol 50 microg/actuation), 1 inhalation b.i.d., in patients with severe asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2012

At a glance

  • Drugs Beclometasone; Beclometasone/formoterol; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 03 Jul 2012 Additional trial location (Czech Republic) added as reported by European Clinical Trials Database record.
    • 03 Jul 2012 Actual end date (10 Sep 2009) added as reported by European Clinical Trials Database record.
    • 24 Aug 2011 Planned End Date changed to 14 Mar 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top